BBLG
Price
$3.49
Change
-$0.13 (-3.59%)
Updated
Jul 3 closing price
Capitalization
1.87M
EXAS
Price
$53.36
Change
-$0.50 (-0.93%)
Updated
Jul 3 closing price
Capitalization
12.78B
30 days until earnings call
Interact to see
Advertisement

BBLG vs EXAS

Header iconBBLG vs EXAS Comparison
Open Charts BBLG vs EXASBanner chart's image
Bone Biologics
Price$3.49
Change-$0.13 (-3.59%)
Volume$131.13K
Capitalization1.87M
Exact Sciences
Price$53.36
Change-$0.50 (-0.93%)
Volume$1.67M
Capitalization12.78B
BBLG vs EXAS Comparison Chart in %
Loading...
BBLG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BBLG vs. EXAS commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBLG is a Hold and EXAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (BBLG: $3.49 vs. EXAS: $53.36)
Brand notoriety: BBLG: Not notable vs. EXAS: Notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BBLG: 20% vs. EXAS: 53%
Market capitalization -- BBLG: $1.87M vs. EXAS: $12.78B
BBLG [@Medical Specialties] is valued at $1.87M. EXAS’s [@Medical Specialties] market capitalization is $12.78B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BBLG’s FA Score shows that 1 FA rating(s) are green whileEXAS’s FA Score has 0 green FA rating(s).

  • BBLG’s FA Score: 1 green, 4 red.
  • EXAS’s FA Score: 0 green, 5 red.
According to our system of comparison, both BBLG and EXAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BBLG’s TA Score shows that 3 TA indicator(s) are bullish while EXAS’s TA Score has 4 bullish TA indicator(s).

  • BBLG’s TA Score: 3 bullish, 6 bearish.
  • EXAS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, EXAS is a better buy in the short-term than BBLG.

Price Growth

BBLG (@Medical Specialties) experienced а -16.11% price change this week, while EXAS (@Medical Specialties) price change was +2.99% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.95%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was -0.02%.

Reported Earning Dates

EXAS is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Medical Specialties (+1.95% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXAS($12.8B) has a higher market cap than BBLG($1.87M). EXAS YTD gains are higher at: -5.036 vs. BBLG (-38.140). EXAS has higher annual earnings (EBITDA): 29.3M vs. BBLG (-9.43M). EXAS has more cash in the bank: 778M vs. BBLG (3.03M). BBLG has less debt than EXAS: BBLG (12.8M) vs EXAS (2.56B). EXAS has higher revenues than BBLG: EXAS (2.5B) vs BBLG (0).
BBLGEXASBBLG / EXAS
Capitalization1.87M12.8B0%
EBITDA-9.43M29.3M-32%
Gain YTD-38.140-5.036757%
P/E RatioN/AN/A-
Revenue02.5B-
Total Cash3.03M778M0%
Total Debt12.8M2.56B1%
FUNDAMENTALS RATINGS
BBLG vs EXAS: Fundamental Ratings
BBLG
EXAS
OUTLOOK RATING
1..100
9760
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
42
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
9251
P/E GROWTH RATING
1..100
65100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BBLG's Valuation (29) in the null industry is in the same range as EXAS (42) in the Biotechnology industry. This means that BBLG’s stock grew similarly to EXAS’s over the last 12 months.

BBLG's Profit vs Risk Rating (100) in the null industry is in the same range as EXAS (100) in the Biotechnology industry. This means that BBLG’s stock grew similarly to EXAS’s over the last 12 months.

EXAS's SMR Rating (97) in the Biotechnology industry is in the same range as BBLG (100) in the null industry. This means that EXAS’s stock grew similarly to BBLG’s over the last 12 months.

EXAS's Price Growth Rating (51) in the Biotechnology industry is somewhat better than the same rating for BBLG (92) in the null industry. This means that EXAS’s stock grew somewhat faster than BBLG’s over the last 12 months.

BBLG's P/E Growth Rating (65) in the null industry is somewhat better than the same rating for EXAS (100) in the Biotechnology industry. This means that BBLG’s stock grew somewhat faster than EXAS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BBLGEXAS
RSI
ODDS (%)
N/A
Bearish Trend 6 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
75%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
73%
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 16 days ago
90%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
77%
Aroon
ODDS (%)
Bullish Trend 6 days ago
43%
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
BBLG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CPAI36.700.37
+1.02%
Counterpoint Quantitative Equity ETF
FUTY52.750.40
+0.76%
Fidelity MSCI Utilities ETF
GSIB44.200.32
+0.74%
Themes Global Systemically Imp Bks ETF
NCV14.200.06
+0.42%
Virtus Convertible & Income Fund
SLNZ47.220.02
+0.03%
TCW Senior Loan ETF

BBLG and

Correlation & Price change

A.I.dvisor tells us that BBLG and EXAS have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BBLG and EXAS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBLG
1D Price
Change %
BBLG100%
-3.59%
EXAS - BBLG
22%
Poorly correlated
-0.93%
XYLO - BBLG
22%
Poorly correlated
-1.07%
PRE - BBLG
22%
Poorly correlated
+1.14%
INBS - BBLG
21%
Poorly correlated
-2.73%
NSPR - BBLG
20%
Poorly correlated
+0.45%
More

EXAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with ILMN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then ILMN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAS
1D Price
Change %
EXAS100%
-0.93%
ILMN - EXAS
36%
Loosely correlated
+0.46%
CDNA - EXAS
35%
Loosely correlated
-1.28%
A - EXAS
33%
Loosely correlated
+0.60%
XRAY - EXAS
33%
Poorly correlated
+0.60%
SNN - EXAS
32%
Poorly correlated
-1.05%
More